Solvonis Therapeutics (LON:SVNS – Get Free Report) announced its quarterly earnings data on Wednesday. The company reported GBX (0.02) earnings per share for the quarter, Digital Look Earnings reports.
Solvonis Therapeutics Price Performance
Shares of SVNS stock opened at GBX 0.11 on Wednesday. The business has a 50-day moving average of GBX 0.13 and a 200 day moving average of GBX 0.19. Solvonis Therapeutics has a 1-year low of GBX 0.10 and a 1-year high of GBX 0.40. The stock has a market capitalization of £8.93 million and a PE ratio of -0.94.
Solvonis Therapeutics Company Profile
Solvonis Therapeutics plc is a clinical-stage biopharmaceutical company headquartered in the United Kingdom. The company is developing a proprietary synthetic exosome platform designed to enhance the targeted delivery of therapeutic compounds. By engineering nanoscale vesicles that mimic natural exosomes, Solvonis aims to improve tissue selectivity, increase payload stability and enable efficient transport of small molecules, peptides and nucleic acids across biological barriers.
The company’s lead programs focus on oncology and central nervous system disorders, where delivery challenges have historically limited the efficacy of novel therapeutics.
See Also
- Five stocks we like better than Solvonis Therapeutics
- Up All Night: How Nasdaq’s 23-Hour Trading Could Wake Up Wall Street
- 4 Stocks That Could Split Next—and Why Investors Are Watching
- Oura’s IPO Freeze Isn’t the Warning Sign It Looks Like
- Bitcoin Is Bouncing Back—Here are 2 Ways to Play the Rebound
Receive News & Ratings for Solvonis Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Solvonis Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
